Abbott Laboratories reported a 29.7 percent rise in quarterly sales on Wednesday, driven by its $25 billion acquisition of St. Jude Medical.
Approval from the U.S. Federal Trade Commission could come as soon as this week or next, said the sources.
Many of the mega M&A deals rarely work out, explains Breakingviews.
Goldman says the strategy of buying the stocks most owned by hedge funds in terms of concentration has outperformed the market since 2001.
CNBC's Landon Dowdy looks into the cybersecurity of medical devices.
CNBC's Landon Dowdy takes a look at health care earnings so far this quarter and provides a preview of what's ahead.
U.S. stock index futures pointed to a flat open, as investors got ready to wade through another influx of earnings reports.
Jamie Dinan and Marc Lasry share their market views in an interview with CNBC's Scott Wapner.
James Dinan, York Capital Management founder and CEO, shares his top stock picks, including St. Jude and Monsanto.
The full interview with York Capital Management's James Dinan and Avenue Capital Group's Marc Lasry.
St. Jude has issued warnings about 400,000 of its heart defibrillators after two people died from malfunctions, NBC News reports.
The “Fast Money” traders and Stephanie Link, TIAA Global Asset Management take their positions on five stocks making news today, including Twilio Inc., Alcoa Inc. and more.
Jim Cramer explains what to watch ahead of the open.
Some of the names on the move ahead of the open.
Short seller Carson Block of Muddy Waters Research sat down with CNBC's Kate Kelly for an exclusive in-depth discussion on his top investment ideas.
Carson Block of Muddy Waters Capital said he is betting against construction firm Tutor Perini during the Sohn San Francisco Investment Conference.
St. Jude Medical on Wednesday filed a lawsuit against short-selling firm Muddy Waters and cyber security company MedSec Holdings.
Alere fell 3 percent after it sued Abbott to compel it to get all antitrust approvals required to complete its $5.8 billion merger.
Shares of St. Jude Medical could drop to $55 or lower if the Abbott Laboratories' deal falls apart, Muddy Waters' Carson Block said.
On Friday, St. Jude refuted Muddy Waters' claims, saying that the "report is false and misleading."